According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

Findings demonstrate ATYR2810's anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.